Syros Pharmaceuticals Inc.

NASDAQ:SYRS   3:59:42 PM EDT
5.28
-0.02 (-0.38%)
Products, Regulatory, Mergers / Acquisitions

Syros Acquires Clinical-Stage Drug Candidate For Acute Promyelocytic Leukemia

Published: 12/05/2020 17:55 GMT
Syros Pharmaceuticals Inc. (SYRS) - Syros Acquires Clinical-stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies.
Syros Pharmaceuticals Inc - Syros Has Made an Upfront Cash Payment of $12 Million to Orsenix.
Syros Pharmaceuticals Inc - Orsenix is Eligible to Receive a $6 Million Regulatory Milestone Related to Development of Sy-2101 in Apl.
Syros Pharmaceuticals Inc - Orsenix is Eligible to Receive Commercial Milestones of Up to $10 Million.
Syros Pharmaceuticals - Orsenix Eligible to Get Single-digit Million Milestone Payments Related to Development of Sy-2101 in Indications Other Than Apl.
Syros Pharmaceuticals Inc - Syros Plans to Initiate a Dose Confirmation Study of Sy-2101 in Second Half of 2021.
Syros - After Dose Showing Comparable Pk to Iv Ato, Intends to Initiate Registration-enabling Phase 3 Trial With Newly Diagnosed Apl in 2022.
Syros Pharmaceuticals Inc - Syros Believes It Could File a New Drug Application (nda) With FDA in 2024.